title: Intracavernous chlorpromazine versus phentolamine: a double-blind clinical comparative study.
abstract: BACKGROUND
  Intracavernous pharmacotherapy is one of the most common treatment modalities of erectile dysfunction (ED). There are different drugs that are used for intracavernous injection including papaverine, phentolamine, prostaglandins E1, phenoxybenzamine, and moxisylate.
  
  
  OBJECTIVE
  The aim of this study is to evaluate the efficacy of chlorpromazine as an intracavernous vasoactive agent alone or with other drugs.
  
  
  METHODS
  This study was performed on 50 patients presenting to our department complaining of ED. Patients were divided into three groups according to the type of intracavernous drug injected. Group A included 20 patients who received an intracavernous injection of 1 mL bimix (30 mg papaverine + 1 mg phentolamine) followed a week later by intracavernous test dose using a 1 mL mixture of papaverine and chlorpromazine (30 mg papaverine + 2.5 mg chlorpromazine). Group B included 20 patients who received an intracavernous injection of 1 mL trimix (30 mg papaverine + 1 mg phentolamine + 10 microg PGE1). A week later they received another intracavernous test dose using a 1 mL mixture of papaverine, PGE1, and chlorpromazine (30 mg papaverine + 2.5 mg chlorpromazine + 10 microg PGE1). Group C included 10 patients who received various intracavernous injections of chlorpromazine in doses 1 mg, 2 mg, 5 mg, and 10 mg.
  
  
  RESULTS
  There was no significant difference in erection response and erection duration between phentolamine and chlorpromazine. Prolonged erection occurred in two patients of group B and postural hypotension occurred in three patients of group C.
  
  
  CONCLUSIONS
  Chlorpromazine can be used as an intracavernous vasoactive agent; it is similar to phentolamine in efficacy and short-term side effect profile.
authors.affiliation: Department of Andrology, Sexology and STDs, Cairo University, Cairo, Egypt. rannone74@hotmail.com
authors.forename: Rany
authors.initials: R
authors.lastname: Shamloul
authors.forename: Mohamed
authors.initials: M
authors.lastname: El-Dakhly
authors.forename: Hussein
authors.initials: H
authors.lastname: Ghanem
authors.forename: Amr
authors.initials: A
authors.lastname: Gadallah
authors.forename: Hany
authors.initials: H
authors.lastname: Mokhtar
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D002746:Chlorpromazine / Q000008:administration & dosage / Q000627:therapeutic use*; D004311:Double-Blind Method; D004333:Drug Administration Routes; D004359:Drug Therapy, Combination; D007172:Erectile Dysfunction / Q000188:drug therapy*; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D010208:Papaverine / Q000627:therapeutic use; D010413:Penis / Q000033:anatomy & histology / Q000098:blood supply / Q000187:drug effects; D010646:Phentolamine / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000317:Adrenergic alpha-Antagonists; D014665:Vasodilator Agents; D010208:Papaverine; D002746:Chlorpromazine; D010646:Phentolamine